Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0907 BTS36 Gerberding Podcast
BioCentury & Getty Images

Back to School 2020

Merck’s Gerberding advocates for a head start on the next pandemic, beginning now: a BioCentury audio interview 

Merck EVP Gerberding wants stockpiles of countermeasures, surge capacity manufacturing and better communication in place for the next time

Merck EVP and former CDC chief Julie Gerberding wants stockpiles of countermeasures, surge capacity manufacturing and better communication for the next time: a BioCentury audio interview.

Sep 7, 2020 | 11:26 PM GMT

First and foremost, the biopharma industry’s lesson from COVID-19 must be to advocate for the kinds of government engagement and investment that can provide a robust platform of countermeasures standing by for the next time they’re needed, according to Merck’s Julie Gerberding, a former CDC chief.

Gerberding, who is EVP and chief patient officer at Merck & Co. Inc. (NYSE:MRK), spoke to BioCentury on an audio interview as part of a series of one-on-one conversations with industry leaders for BioCentury’s 2020 Back to School package (see Cover Story:  “The Imperative of COVID-19”).

Gerberding was director of the  U.S. CDC in 2002-09, and oversaw its activities during the 2003 SARS outbreak. 

She said when COVID-19 hit, the response got off “on the wrong foot from the

Read the full 2000 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE